lacidipine
Trade name: motens
Small moleculeexperimental
Lacidipine is a calcium channel blocker. It is available as tablets containing 2 or 4 mg. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
5
Earliest trial started Jun 1, 1995 (NCT02177331)
Timeline
Indications
Approved for
Mechanism of action
Voltage-gated L-type calcium channel blocker
- Voltage-gated L-type calcium channelINHIBITOR
Voltage-gated L-type calcium channel inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C- Mol. weight
- 455.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLacidipine ↗
- ChEMBLCHEMBL460291 ↗
Also known as
- boehringer ingelheim brand of lacidipine
- caldine
- caldine
- caldine
- diethyl 2,6-dimethyl-4-(2-((e)-2-((2-methylpropan-2-yl)oxycarbonyl)ethenyl)phenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- glaxosmithkline brand of lacidipine
- gr 43659x
- gr-43659x
- gr-43659x
- gr-43659x
- gr-43659x
- lacidipine
- lacidipine
- lacidipine
- lacidipine
- lacidipine
- lacidipine
- lacidipine
- lacidipine
- lacimen
- lacipil
- lacipil
- lacirex
- menarini brand of lacidipine
- molap
- motens
- motens
- motens
- motens
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00533858 | Phase 4 | Sep 1, 2007 | Seoul National University |
| NCT00460915 | Phase 4 | Jan 1, 2007 | GlaxoSmithKline, Korea University |
| NCT00338338 | Phase 4 | Nov 1, 2005 | GlaxoSmithKline |
| NCT00328965 | Phase 4 | Nov 1, 2004 | GlaxoSmithKline |
| NCT02264158 | Phase 1 | Sep 1, 2001 | Boehringer Ingelheim |
| NCT02209649 | Phase 1 | Oct 1, 1999 | Boehringer Ingelheim |
| NCT02203500 | Phase 1 | Oct 1, 1998 | Boehringer Ingelheim |
| NCT02218684 | Phase 1 | Sep 1, 1998 | Boehringer Ingelheim |
| NCT02232607 | Phase 2 | Apr 1, 1998 | Boehringer Ingelheim |
| NCT02235402 | Phase 4 | Dec 1, 1997 | Boehringer Ingelheim |
| NCT02177331 | Phase 3 | Jun 1, 1995 | Boehringer Ingelheim |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 7 | 7 | 4 | 1995 |
| GlaxoSmithKline | For profit | 3 | 2 | 1 | 2004 |
| Korea University | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2007 |
4 organizations
Page 1 / 1